For example, tamoxifen, an FDA-approved inhibitor of the protein kinase C genes PRKCB and PRKCE, currently used for breast cancer treatment, could potentially be used to target EGFR or KRAS-mutated lung cancers and NRAS-mutated skin cancer. Here, KRAS is linked to breast carcinoma.